Environmental Virology Cell (EVC), Council of Scientific and Industrial Research-National Environmental Engineering Research Institute (CSIR-NEERI), Nagpur, India.
Academy of Scientific and Innovative Research (AcSIR), New Delhi, India.
Front Public Health. 2023 Jun 27;11:1117602. doi: 10.3389/fpubh.2023.1117602. eCollection 2023.
Being the second most populous country in the world, India presents valuable lessons for the world about dealing with the SARS-CoV-2 pandemic. From this perspective, we attempted a retrospective evaluation of India's SARS-CoV-2 genomic surveillance strategy and also gave some recommendations for undertaking effective genomic surveillance. The dynamics of the COVID-19 pandemic are continuously evolving, and there is a dire need to modulate the genomic surveillance strategy accordingly. The pandemic is now settling towards a low positivity rate scenario, so it is required to revise the practices and policies formulated for a high positivity rate scenario. The perspective also recommends adopting a decentralised approach for SARS-CoV-2 genomic surveillance with a focus on optimising the workflow of SARS-CoV-2 genomic surveillance to ensure early detection of emerging variants, especially in the low positivity rate scenario. The perspective emphasises a key observation that the SARS-CoV-2 genomic surveillance is an important mitigation effort during the pandemic, the guards of such mitigation efforts should not be lowered during the low positivity rate scenario. We attempt to highlight the limitations faced by the Indian healthcare administration during the SARS-CoV-2 genomic surveillance and, simultaneously, suggest policy interventions derived from our first-hand experience, which may be implementable in a vast, populated country like India.
作为世界上第二大人口大国,印度为全球应对 SARS-CoV-2 大流行提供了宝贵的经验。从这个角度出发,我们尝试对印度 SARS-CoV-2 基因组监测策略进行回顾性评估,并为开展有效的基因组监测提出了一些建议。COVID-19 大流行的动态在不断演变,因此需要相应地调整基因组监测策略。目前大流行正处于低阳性率阶段,因此需要修订为高阳性率阶段制定的实践和政策。该观点还建议采用去中心化的 SARS-CoV-2 基因组监测方法,重点优化 SARS-CoV-2 基因组监测的工作流程,以确保及早发现新出现的变异株,尤其是在低阳性率阶段。该观点强调了一个重要的观察结果,即 SARS-CoV-2 基因组监测是大流行期间的一项重要缓解措施,在低阳性率阶段不应降低这种缓解措施的警惕性。我们试图强调印度医疗保健管理在 SARS-CoV-2 基因组监测方面所面临的限制,并同时提出源自我们第一手经验的政策干预措施,这些措施在像印度这样人口众多的国家可能是可行的。